AzTrials
AzTrials

Male InfertilityAndrofertiNCT03466229

Impact of Antioxidant Treatment on DNA Fragmentation Index

A study testing Androferti in people with Male Infertility, run by Region Skane.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants. Read more about this study

Who is it for?
Ages 18 to 50 years, women only
Conditions the study is for
Male Infertility
What is being tested?
Androferti
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
79 participants
Where
No sites listed yet
Study dates
1 Jul 2015to 31 Dec 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Referred due to infertility
  • Age: 18-50 years,
  • Non-smoking,
  • Sperm DNA Fragmentation Index >25%

Who cannot join

  • Body mass index (BMI) ≥30,
  • FSH outside the normal range of 2-8 IU/L,g)
  • LH outside the normal range of 2-10 IU/L,
  • T < 10nmol/L
  • Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
  • History of anabolic steroids use,
  • Taking antioxidant supplementation the last six months.

About this study

Official title: Impact of Antioxidant (Androferti) Treatment on Sperm DNA Integrity

Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.

Read the detailed description

In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant.

Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities.

Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient ~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis.

The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome.

Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting.

The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options .

The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.

Being tested
Androferti, Placebo
Keywords
sperm DNA strand breaks, antioxidants
Medical subject headings
Infertility, Male

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AndrofertiDietary supplement

  • PlaceboDietary supplement

Study groups in NCT03466229
Study groupRoleWhat they receive
AntioxidantActive comparatorAndroferti - 1 twice per day
Receives: Dietary Supplement: Androferti
PlaceboPlacebo comparatorPlacebo - 1 twice per day
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. DFI_3

    3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin

    Measured: Change in DNA Fragmentation Index from Baseline to 3 months

  2. DFI_6

    6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay

    Measured: Change in DNA Fragmentation Index from Baseline to 6 months

Secondary outcomes (6)
  1. Concentration_3

    Change sperm concentration 3 months

    Measured: Change in sperm concentration from baseline to 3 months in millions/mL

  2. Concentration_6

    Change sperm concentration 6 months

    Measured: Change in sperm concentration from baseline to 6 months in millions/mL

  3. Motility_3

    Change sperm motility 3 months

    Measured: Change in sperm motility from baseline to 3 months in %

  4. Motility_6

    Change sperm motility 6 months

    Measured: Change in sperm motility from baseline to 6 months in %

  5. Morphology_3

    Change sperm morphology 3 months

    Measured: Change in sperm morphology from baseline to 3 months in %

  6. Morphology_6

    Change sperm morphology 6 months

    Measured: Change in sperm morphology from baseline to 6 months in %

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2018
  2. Study start1 Jul 2015
  3. Primary completion31 Dec 2016
  4. Study completion31 Dec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blind randomised placebo controlled study
Masking
Single blind
Who is masked
Investigator
Enrolment
79 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03466229
Sponsor's protocol ID
Androferti
Acronym
Androferti
Status last verified
Mar 2018
First submitted
4 Mar 2018
Last updated
16 Mar 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Plan to share IPD has not yet been discussed

Publications

  • Stenqvist A, Oleszczuk K, Leijonhufvud I, Giwercman A. Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology. 2018 Nov;6(6):811-816. doi: 10.1111/andr.12547. Epub 2018 Oct 8.

    PubMed 30298673

Questions about this trial

What is this clinical trial studying?

A study testing Androferti in people with Male Infertility, run by Region Skane.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

DFI_3 (time frame: Change in DNA Fragmentation Index from Baseline to 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03466229, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in